In the present work, we identify CDC7 inhibition as a potential therapeutic approach in two different settings: inhibition of NE transformation from adenocarcinomas on targeted therapy, and treatment of NE carcinomas, either de novo or following histological transformation. The gene discussed is CDC7; the disease is adenocarcinoma.